Abstract
Metabolism Once imported into cells and phosphorylated, the glucose analog 2-deoxyglucose (2DG) inhibits glycolysis. As glycolysis is up-regulated in many cancers, 2DG has been proposed as a treatment. Using yeast as a model, Defenouillere et al. investigated how cells become resistant to 2DG. Exposure to 2DG activated several signaling pathways, resulting in the increased expression of the gene encoding the phosphatase Dog2. When overexpressed, a human homolog of Dog2 conferred 2DG resistance to human cells, suggesting that cancer cells with increased abundance of this phosphatase could escape the toxic effects of 2DG. Sci. Signal. 12 , eaaw8000 (2019).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
